GlassScriptPhysician profile
Mahmoud Mohamed
NPI 1679569222
$11,939.38
in general payments reported to CMS, 2019-2025
41 companies · $971 in 2025
The $971 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $1,799 · 2021: $2,406 · 2022: $2,426 · 2023: $1,789 · 2024: $750 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.52 |
| Education | $178.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,826.53 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $1,970.50 | 2021-2025 | |
| Allergan, INC. | $1,469.65 | 2019-2022 | |
| Amgen INC. | $934.00 | 2019-2024 | Aimovig |
| Biogen, INC. | $686.28 | 2019-2022 | |
| Lilly USA, LLC | $513.38 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $364.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $306.77 | 2019-2023 | |
| Genzyme Corporation | $292.38 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $285.85 | 2020-2021 | |
| Ucb, INC. | $207.29 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $195.42 | 2023 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $178.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $174.65 | 2021 | |
| Upsher-Smith Laboratories LLC | $156.72 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.